Fbxw13 Activators
Fbxw13 Activators is a nomenclature used to describe a collection of chemical compounds that influence the functional activity of the Fbxw13 protein indirectly. Fbxw13 is a part of the SCF (Skp1-Cul1-F-box protein) complex, which functions as an E3 ubiquitin ligase, responsible for tagging specific proteins for degradation by the 26S proteasome. These activators do not directly bind to or modify Fbxw13; instead, they exert their effect by modulating the ubiquitin-proteasome system (UPS), leading to a cellular environment that requires elevated ubiquitin ligase activity. Such compounds are usually involved in the inhibition of the proteasome, a multi-protein complex that degrades unneeded or damaged proteins that have been ubiquitinated. By preventing the breakdown of these proteins, Fbxw13 activators cause an accumulation of ubiquitinated proteins within the cell. This accrual challenges the cellular machinery to maintain protein homeostasis, which may result in a compensatory upregulation of the ubiquitination process in which Fbxw13 is a key player.
The chemistry of Fbxw13 activators is diverse, encompassing various molecular structures that share the functional outcome of proteasome inhibition. For instance, compounds like MG132, Bortezomib, and Carfilzomib are characterized by their ability to bind to the catalytic sites of the proteasome, thus blocking its proteolytic functions. On the other hand, molecules such as PYR-41 target upstream enzymatic activities necessary for the ubiquitination process; PYR-41 specifically inhibits the ubiquitin-activating enzyme E1. Another example is MLN4924, which inhibits the NEDD8-activating enzyme essential for the neddylation process that regulates the activity of E3 ubiquitin ligases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that leads to the accumulation of ubiquitinated proteins by preventing their degradation. This accumulation can indirectly enhance the activity of Fbxw13 as it increases the cellular demand for ubiquitination, a process in which Fbxw13 is involved. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Another proteasome inhibitor that, like MG132, causes a build-up of ubiquitinated proteins. This build-up may indirectly necessitate an increase in Fbxw13 function due to the elevated need for ubiquitin ligase activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A specific proteasome inhibitor that can lead to an indirect enhancement of Fbxw13 activity by increasing the levels of proteins needing ubiquitination in the cellular environment. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of the ubiquitin-activating enzyme E1, leading to reduced ubiquitination and potentially enhancing the activity of Fbxw13 as the cell adjusts to manage protein quality control. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
An inhibitor of the NEDD8-activating enzyme which modulates neddylation, a process similar to ubiquitination. By inhibiting neddylation, MLN4924 can indirectly increase the demand for ubiquitin ligase activity, thereby enhancing the functional activity of Fbxw13. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
A proteasome inhibitor that may indirectly lead to increased functional activity of Fbxw13 by leading to the accumulation of polyubiquitinated substrates. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
A proteasome inhibitor that can lead to a higher functional activity of Fbxw13 as it causes an accumulation of proteins that would otherwise be degraded, thus potentially enhancing the ubiquitin ligase activity of Fbxw13. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An oral proteasome inhibitor that may enhance the activity of Fbxw13 by increasing the substrate availability for ubiquitination due to inhibition of proteasomal degradation. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Similar to other proteasome inhibitors, ixazomib can indirectly lead to an enhancement of Fbxw13 activity by increasing the pool of ubiquitinated proteins within the cell. | ||||||